Antares Pharma (ATRS) Reports In-Line Q2 Loss
Tweet
Share
E-mailGet Alerts ATRS Hot Sheet
Join SI Premium – FREE
Antares Pharma (NASDAQ: ATRS) reported Q2 EPS of ($0.07), in-line with the analyst estimate of ($0.07). Revenue for the quarter came in at $6.3 million versus the consensus estimate of $6.43 million.
For earnings history and earnings-related data on Antares Pharma (ATRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
- Actelis Networks (ASNS) Tops Q2 EPS by 63c
- Immucell Corp (ICCC) Reports Q2 EPS of $0.20
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
